ArticleCancer discovery2020

Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with

Timothy A Yap et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.